media.tenor.com
the joker is leaning against a wall with his face painted and making a funny face .
ALT: the joker is leaning against a wall with his face painted and making a funny face .
Feed collects the Myers-Briggs personality type posts. // Made at BlueskyFeeds.com
Feed on Blueskymedia.tenor.com
the joker is leaning against a wall with his face painted and making a funny face .
ALT: the joker is leaning against a wall with his face painted and making a funny face .
And staring at me because I’m black, wondering when the black will show ie anger and aggression Not realising, I am black alright…there’s no in between with me. Your life was in danger madame fake doctor lady, every single day you had me in there that close to your insanity :) Millions please.
media.tenor.com
www.stocktitan.net
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 INDEPENDENCE trial for Reblozyl® (luspatercept-aamt) did not meet its primary endpoint in treating myelofibrosis-associated anemia. Despite missing statistical significance (p=0.0674), the trial showed clinically meaningful improvements in red blood cell transfusion independence.The study demonstrated positive secondary outcomes, including a higher number of patients achieving a 50% reduction in RBC transfusion burden and increased hemoglobin levels while maintaining transfusion independence. The safety profile remained consistent with previous findings across indications. Despite not meeting the primary endpoint, BMS plans to engage with FDA and EMA regarding potential marketing applications based on the overall positive clinical benefits observed.